The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

The development of immune checkpoint inhibitors has changed the treatment paradigm for advanced cancers across many tumor types. Despite encouraging and sometimes durable responses in a subset of patients, most patients do not respond. Tumors have adopted the PD-1/PD-L1 axis for immune escape to fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Andrew A., Patel, Vaibhav G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815032/
https://www.ncbi.nlm.nih.gov/pubmed/31655605
http://dx.doi.org/10.1186/s40425-019-0768-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815032/
https://www.ncbi.nlm.nih.gov/pubmed/31655605
http://dx.doi.org/10.1186/s40425-019-0768-9

Ejemplares similares